These findings substantiate previous studies that indicates that KDM5B enhances cancer drug resistance in neuroblastoma Cells [44, 46], glioblastoma [47], hepatocellular carcinoma [45], melanoma [48], and gastric cancer [49]. This evidence concerns the gene KDM5B and hepatocellular carcinoma.